Tumor mutation burden: from comprehensive mutational screening to the clinic
Open Access
- 7 August 2019
- journal article
- review article
- Published by Springer Nature in Cancer Cell International
- Vol. 19 (1) , 1-10
Abstract
The recent advent of immunomodulatory therapies into the clinic has demanded the identification of innovative predictive biomarkers to identify patients most likely to respond to immunotherapy and support the design of tailored clinical trials. Current molecular testing for selection of patients with gastrointestinal or pulmonary carcinomas relies on the prevalence of PD-L1 expression in tumor as well as immune cells by immunohistochemistry and/or on the evaluation of the microsatellite status. Tumor Mutational Burden (TMB) has emerged as a promising novel biomarker in this setting to further aid in patient selection. This has been facilitated by the increasing implementation of molecular pathology laboratories with comprehensive next generation sequencing (NGS) technologies. However, the significant overall costs and expertise required for the interpretation of NGS data has limited TMB evaluation in routine diagnostics, so far. This review focuses on the current use of TMB analysis in the clinical setting in the context of immune checkpoint inhibitor therapies.Keywords
This publication has 40 references indexed in Scilit:
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicityJournal of Experimental Medicine, 2014
- Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemiaBlood, 2014
- A vaccine targeting mutant IDH1 induces antitumour immunityNature, 2014
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive MelanomaJournal of Clinical Oncology, 2013
- Signatures of mutational processes in human cancerNature, 2013
- Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cellsNature Medicine, 2013
- Exploiting the Mutanome for Tumor VaccinationCancer Research, 2012
- Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoeditingNature, 2012